- Home
- BSBR vs ALNY Comparison
BSBR vs ALNY Comparison
Compare BSBR & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSBR
- ALNY
- Stock Information
- Founded
- BSBR 1985
- ALNY 2002
- Country
- BSBR Brazil
- ALNY United States
- Employees
- BSBR N/A
- ALNY N/A
- Industry
- BSBR Commercial Banks
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- BSBR Finance
- ALNY Health Care
- Exchange
- BSBR Nasdaq
- ALNY Nasdaq
- Market Cap
- BSBR 31.3B
- ALNY 33.2B
- IPO Year
- BSBR 2009
- ALNY 2004
- Fundamental
- Price
- BSBR $4.33
- ALNY $273.99
- Analyst Decision
- BSBR Buy
- ALNY Buy
- Analyst Count
- BSBR 1
- ALNY 24
- Target Price
- BSBR $6.00
- ALNY $299.09
- AVG Volume (30 Days)
- BSBR 757.2K
- ALNY 646.7K
- Earning Date
- BSBR 02-05-2025
- ALNY 02-13-2025
- Dividend Yield
- BSBR 6.31%
- ALNY N/A
- EPS Growth
- BSBR 26.22
- ALNY N/A
- EPS
- BSBR 0.30
- ALNY N/A
- Revenue
- BSBR $8,670,618,732.00
- ALNY $2,094,795,000.00
- Revenue This Year
- BSBR N/A
- ALNY $24.82
- Revenue Next Year
- BSBR N/A
- ALNY $19.89
- P/E Ratio
- BSBR $7.04
- ALNY N/A
- Revenue Growth
- BSBR 8.02
- ALNY 21.54
- 52 Week Low
- BSBR $3.75
- ALNY $141.98
- 52 Week High
- BSBR $6.02
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- BSBR 60.03
- ALNY 62.58
- Support Level
- BSBR $4.14
- ALNY $273.33
- Resistance Level
- BSBR $4.37
- ALNY $287.22
- Average True Range (ATR)
- BSBR 0.08
- ALNY 11.37
- MACD
- BSBR 0.04
- ALNY 3.75
- Stochastic Oscillator
- BSBR 90.70
- ALNY 75.68
About BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.